Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 801 results for "alexion pharmaceuticals"

Julie Oneill Sells 2,858 Shares of Alexion Pharmaceuticals, Inc. (ALXN) Stock
American Banking News - Earnings

Cumberland Partners Ltd Decreases Position in Alexion Pharmace...

Cumberland Partners Ltd decreased its stake in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 169,350 ... Mideast Time, 8 hours ago
[x]  

21 images for alexion pharmaceuticals

American Banking News - Earnings, 14 hours ago
Octafinance, 5 days ago
Octafinance, 5 days ago
Octafinance, 6 days ago
Jutia Group, 6 days ago
Octafinance, 5 days ago
Octafinance, 5 days ago
Octafinance, 6 days ago
Providence Business News, 1 week ago
Jutia Group, 2 weeks ago

SC 13G/A - ALEXION PHARMACEUTICALS INC (0000899866) (Subject)

Form SC 13G - Statement of acquisition of beneficial ownership by individuals [amend] SEC Accession No. 0000215457-16-005438 Filing Date 2016-02-10 Accepted 2016-02-10 10:15:52 Documents 1 Filing Date Changed 2016-02-10 Document Format Files Seq ...
 SEC15 hours ago ALEXION PHARMACEUTICALS INC (0000899866) (Subject)  SEC Filings15 hours ago 8-A12G - ALEXION PHARMACEUTICALS INC (0000899866) (Filer)  SEC5 days ago 10-K - ALEXION PHARMACEUTICALS INC (0000899866) (Filer)  SEC2 days ago
Motley Fool

The Key Takeaways From Alexion Pharmaceuticals Inc.'s Earnings Release

Image by TBIT via Pixabay. Biotech heavyweight Alexion Pharmaceuticals ( NASDAQ:ALXN ) released its fourth-quarter 2015 earnings results before the opening bell Wednesday. Like many other biotechs, Alexion's shares have taken a beating recently, ...
 Motley Fool5 days ago

'Mad Money' Lightning Round: Take Celgene Over Alexion Pharmaceuticals

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. Here's what Jim Cramer had to say about some of the stocks during the Mad Money Lightning Round Wednesday evening: Sysco (SYY - Get Report) : ...
 TheStreet.com6 days ago Celgene Is Down Enough To Be Bought - Cramer's Lightning Round (2/3/16)  Seeking Alpha6 days ago Lightning Round: This energy stock goes higher  CNBC1 week ago
Zacks.com

Alexion (ALXN) Misses on Q4 Earnings and Revenues

Alexion Pharmaceuticals ALXN focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic ...
 Yahoo! Finance1 week ago Alexion Misses on Earnings and Revenues in Q4, Gives View  Zacks.com1 week ago
[x]  
Nasdaq

Alexion Pharmaceuticals (ALXN) Q4 2015 Results - Earnings Call Webcast

| About: Alexion Pharmaceuticals, Inc. (ALXN) The following audio is from a conference call that will begin on February 03, 2016 at 10:00 AM ET. The audio will stream live while the call is active, and can be replayed upon
 Seeking Alpha1 week ago Alexion Pharmaceuticals Q4 15 Earnings Conference Call At 10:00 AM ET  Nasdaq1 week ago

Trade-Ideas: Alexion Pharmaceuticals (ALXN) Is Today's Unusual Social Activity Stock

Trade-Ideas LLC identified Alexion Pharmaceuticals ( ALXN) as an unusual social activity candidate. In addition to specific proprietary factors, Trade-Ideas identified Alexion Pharmaceuticals as such a stock due to the following factors: ALXN has ...
 TheStreet.com1 week ago

Alexion Pharma Q4 top line up 17%; EPS down 62%; shares down 5% premarket

Alexion Pharmaceuticals (NASDAQ: ALXN ) Q4 results ($M): Total Revenues: 700.9 (+16.9%); Net Product Sales: 700.4 (+16.8%); Soliris Sales: 688.5 (+14.8%); Kanuma Sales: 336. Net Income: 66.6 (-56.6); EPS: 0.29 (-61.8%). 2016 Guidance : Total ...
 Seeking Alpha1 week ago

Alexion Issues 2016 Guidance - Quick Facts

Alexion Pharmaceuticals, Inc. (ALXN) announced on a non-GAAP and constant currency basis, for 2016, the company expects: total product revenues in the range of $3.17 to $3.22 billion; and earnings per share of $5.31 to $5.51. Based on forecasted ...
 RTTNews.com1 week ago

Alexion Pharmaceuticals beats by $0.03, misses on revenue

s Editor Alexion Pharmaceuticals (NASDAQ:ALXN): Q4 EPS of $1.13 beats by $0.03. Revenue of $700.87M (+16.9% Y/Y) misses
 Seeking Alpha1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - alexion pharmaceuticals
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less